Community Portal

A place for Clinicians and Healthcare Suppliers to share knowledge and learn more about THE CLINICIAN EXCHANGE



Provided by: Medscape

FDA Expands CF Drug Kalydeco to Children as Young as Age 1 Year

Published: Fri, 17 Aug 2018 13:06:40 EDT
The drug is indicated for children as young as 12 months with at least one mutation in the CFTR gene that is responsive to the drug, as determined from clinical or in vitro assay data.
FDA Approvals

FDA Flags Temporary Artificial Heart for Mortality, Stroke Risk

Published: Fri, 17 Aug 2018 13:02:40 EDT
The letter to healthcare providers was issued after the agency reviewed final results of a postmarket study conducted by the device maker, SynCardia Systems.
News Alerts

Lectins: Are These Food-Based Proteins Friend or Foe?

Published: Fri, 17 Aug 2018 12:09:27 EDT
With limited data or logic to back them up, lectins are now under scrutiny.

AI System Accurately Detects 53 Kinds of Eye Disease

Published: Fri, 17 Aug 2018 11:12:17 EDT
In 'jaw-dropping' trial results, researchers find that an artificial intelligence system was as effective as some of the world's best eye experts in spotting diseases that could lead to blindness.
Medscape Medical News
Displaying results 5-8 (of 20)
 1 - 2 - 3 - 4 - 5 


Duke antidepressant startup Evecxia brings on ex-Cerecor chief as CEO

Published: Thu, 16 Aug 2018 13:59:52 +0000
Evecxia has officially named John Kaiser as its CEO and interim chairman of its board of directors. Kaiser has been working with the Duke University spinout’s management since March.

EuroBiotech Report—Pfizer-BioNTech, U.K. biotechs raise $247M and Vernalis accepts buyout bid

Published: Thu, 16 Aug 2018 13:01:43 +0000
In this week's EuroBiotech Report, Pfizer and BioNTech ink a $425 million deal, British biotechs reel in $247 million in VC cash and more.

Too scared to speak in public? Biohaven says it has a drug that can help

Published: Thu, 16 Aug 2018 12:59:23 +0000
Biohaven’s new formulation of amyotrophic lateral sclerosis drug riluzole has helped people with social anxiety face the challenge of speaking in public.

Regeneron, Teva’s pain drug clears phase 3 efficacy bar

Published: Thu, 16 Aug 2018 12:44:56 +0000
A phase 3 osteoarthritis trial of Teva and Regeneron’s fasinumab has met its co-primary endpoints. The anti-NGF antibody cleared the efficacy bar but triggered the expected safety alarms, keeping it on the tail of Pfizer and Eli Lilly’s rival asset without dispelling doubts about its prospects.
Displaying results 5-8 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy